公开(公告)号：US20200064337A1

公开(公告)日：2020-02-27

申请号：US16391063

申请日：2019-04-22

申请人： Berkeley Lights, Inc.

发明人： Minha Park ,  Jason C. Briggs ,  Jason M. McEwen ,  Ravi K. Ramenani ,  Hariharasudhan Chirra Dinakar ,  Kai W. Szeto ,  Adrienne T. Higa ,  Mark P. White ,  Randall D. Lowe, JR. ,  Xiaohua Wang ,  Kevin T. Chapman

IPC分类号： G01N33/50 ,  B01L3/00 ,  C12N5/0781 ,  G01N33/68 ,  C12Q1/6876

摘要： Methods are described herein for screening an antibody producing cell within a microfluidic environment. The antibody producing cell may be a B cell lymphocyte, which may be a memory B cell or a plasma cell. An antigen of interest may be brought into proximity with the antibody producing cell and binding of the antigen by an antibody produced by the antibody producing cell may be monitored. Methods of obtaining a sequencing library from an antibody producing cell are also described.

公开(公告)号：US20190283026A1

公开(公告)日：2019-09-19

申请号：US16253869

申请日：2019-01-22

申请人： Berkeley Lights, Inc.

发明人： Kevin D. Loutherback ,  Yelena Bronevetsky ,  Peter J. Beemiller ,  Xiaohua Wang ,  Kevin T. Chapman

IPC分类号： B01L3/00 ,  G01N1/34 ,  A61K35/17

摘要： Methods of sorting T lymphocytes in a microfluidic device are provided. The methods can include flowing a fluid sample comprising T lymphocytes through a region of a microfluidic device that contains an array of posts. The array of posts can be configured to have a critical size (Dc) that separates activated T lymphocytes from naïve T lymphocytes. Also provided are microfluidic devices having an array of posts configured to separate activated T lymphocytes from naïve T lymphocytes, compositions enriched for T lymphocytes, particularly activated T lymphocytes that are known to be reactive to an antigen of interest, and methods of treating subjects suffering from a pathogenic disorder or cancer by administering such compositions.

公开(公告)号：US11273177B2

公开(公告)日：2022-03-15

申请号：US15488139

申请日：2017-04-14

申请人： Berkeley Lights, Inc.

发明人： Kevin T Chapman ,  Xiaohua Wang ,  Xiao Guan Radstrom ,  Yelena Bronevetsky ,  Guido K Stadler ,  Gregory G Lavieu ,  Annamaria Mocciaro

IPC分类号： A61K35/17 ,  C07K14/55 ,  C12N9/24 ,  C07K16/28 ,  B01L3/00 ,  C07K14/195 ,  C12N5/0783 ,  A61K31/65 ,  C12N5/00 ,  C12N5/0781 ,  C07K14/47 ,  C07K14/52 ,  A61K39/00

摘要： The present disclosure provides methods of preparing tumor infiltrating cells engineered to express a pro-inflammatory polypeptide. The pro-inflammatory polypeptide is expressed from the tumor infiltrating cell to counter a generally immunosuppressive state in and around tumors resulting from an imbalance between the number and activation state of immune effector cells versus those of suppressor cells. Delivering the proinflammatory polypeptide via expression from the TICs, as distinct from systemic administration, reduces side effects from increased inflammation at sides remote from a tumor to be treated.

公开(公告)号：US20210087252A1

公开(公告)日：2021-03-25

申请号：US16987835

申请日：2020-08-07

申请人： Berkeley Lights, Inc. ,  The Regents of the University of California

发明人： Hideho Okada ,  Duane Smith ,  Payal Watchmaker ,  Yelena Bronevetsky ,  Ryosuke Naka ,  Guido K. Stadler ,  Xiaohua Wang ,  Kevin T. Chapman

IPC分类号： C07K14/725 ,  C12N5/0783 ,  C12N15/63

摘要： This disclosure relates to the production and use of an isolated, purified and/or recombinant T cell receptor (TCR) that specifically binds to a mutant IDH1 protein, or a fragment thereof, wherein the mutant IDH1 protein or fragment thereof comprises an R132H mutation.

公开(公告)号：US20210011015A1

公开(公告)日：2021-01-14

申请号：US16908265

申请日：2020-06-22

申请人： Berkeley Lights, Inc.

发明人： Kristin G. Beaumont ,  Peter J. Beemiller ,  Volker L.S. Kurz ,  Gregory G. Lavieu ,  Xiaohua Wang ,  Aathavan Karunakaran

IPC分类号： G01N33/543 ,  B01L3/00 ,  G01N33/545 ,  G01N33/58

摘要： In situ-generated microfluidic capture structures incorporating a solidified polymer network, methods of preparation and use, compositions and kits therefor are described. Microfluidic capture structures may be advantageously used for assays performed within the microfluidic environment, providing flexibility in assaying micro-objects such as biological cells. Assay reagents and analytes may be incorporated within the microfluidic capture structures.

公开(公告)号：US10829728B2

公开(公告)日：2020-11-10

申请号：US16010176

申请日：2018-06-15

申请人： Berkeley Lights, Inc.

发明人： Volker L. S. Kurz ,  Troy A. Lionberger ,  Eric K. Sackmann ,  Kai W. Szeto ,  Paul M. Lebel ,  Brandon R. Bruhn ,  Keith J. Breinlinger ,  Eric D. Hobbs ,  Andrew W. McFarland ,  J. Tanner Nevill ,  Xiaohua Wang

IPC分类号： B01L3/00 ,  C12M3/06 ,  C12M1/00 ,  C12M1/26

摘要： Apparatuses and methods are described for the use of optically driven bubble, convective and displacing fluidic flow to provide motive force in microfluidic devices. Alternative motive modalities are useful to selectively dislodge and displace micro-objects, including biological cells, from a variety of locations within the enclosure of a microfluidic device.

公开(公告)号：US10712344B2

公开(公告)日：2020-07-14

申请号：US15406289

申请日：2017-01-13

申请人： Berkeley Lights, Inc.

发明人： Kevin T. Chapman ,  George L. Fox ,  Peggy A. Radel ,  Mark P. White ,  Xiaohua Wang ,  Minha Park ,  Guido K. Stadler ,  Randall D. Lowe, Jr. ,  Xiao Guan Radstrom ,  Jason M. McEwen ,  Gang F. Wang

IPC分类号： B01L3/00 ,  G01N33/574 ,  C07K16/00 ,  G01N33/569 ,  C07K16/28 ,  G01N33/50 ,  C07K16/30 ,  C12Q1/6886 ,  G01N33/543

摘要： A method of preparing an antibody therapeutic is provided comprising: (a) providing a dissociated cell sample from at least one solid tumor sample obtained from a patient; (b) loading the dissociated cell sample into a microfluidic device having a flow region and at least one isolation region fluidically connected to the flow region; (c) moving at least one B cell from the dissociated cell sample into at least one isolation region in the microfluidic device, thereby obtaining at least one isolated B cell; and (d) using the microfluidic device to identify at least one B cell that produces antibodies capable of binding to cancer cells. The cancer cells can be the patient's own cancer cells. Also provided are methods of treating patients, methods of labeling or detecting cancer, engineered T or NK cells comprising antibodies or fragments thereof, and engineered antibody constructs.

公开(公告)号：US20170224734A1

公开(公告)日：2017-08-10

申请号：US15488139

申请日：2017-04-14

申请人： Berkeley Lights, Inc.

发明人： Kevin T Chapman ,  Xiaohua Wang ,  Xiao Guan Radstrom ,  Yelena Bronevetsky ,  Guido K Stadler ,  Gregory G Levieu ,  Annamaria Mocciaro

IPC分类号： A61K35/17 ,  C07K14/55 ,  C12N9/24 ,  C07K16/28 ,  B01L3/00 ,  C07K14/195 ,  C12N5/0783 ,  A61K31/65

CPC分类号： A61K35/17 ,  A61K31/65 ,  B01L3/50273 ,  B01L3/502761 ,  B01L2300/0861 ,  B01L2300/0896 ,  B01L2400/0424 ,  C07K14/195 ,  C07K14/4748 ,  C07K14/52 ,  C07K14/55 ,  C07K16/2818 ,  C07K2317/14 ,  C07K2319/00 ,  C12N5/00 ,  C12N5/0635 ,  C12N5/0636 ,  C12N5/0637 ,  C12N5/0638 ,  C12N9/2402 ,  C12N2501/04 ,  C12N2510/00 ,  C12Y302/01166

摘要： The present disclosure provides methods of preparing tumor infiltrating cells engineered to express a pro-inflammatory polypeptide. The pro-inflammatory polypeptide is expressed from the tumor infiltrating cell to counter a generally immunosuppressive state in and around tumors resulting from an imbalance between the number and activation state of immune effector cells versus those of suppressor cells. Delivering the proinflammatory polypeptide via expression from the TICs, as distinct from systemic administration, reduces side effects from increased inflammation at sides remote from a tumor to be treated.